Pharmacologic Treatment of Obsessive-compulsive Disorder
2006; Slack Incorporated (United States); Volume: 36; Issue: 7 Linguagem: Inglês
10.3928/00485713-20060701-02
ISSN1938-2456
Tópico(s)Pharmaceutical industry and healthcare
Resumo<P>The main goal of treatment for obsessive-compulsive disorder (OCD) is to reduce the severity and the intrusiveness of obsessions and compulsions so as to improve the patient’s quality of life. This article reviews current pharmacologic treatments for OCD, including a comprehensive review of the literature regarding the effectiveness of various agents, as well as their side effects and factors affecting treatment response in individual patients.</P> <H4>ABOUT THE AUTHORS</H4> <P>Dr. Marazziti is professor of psychiatry, Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie, University of Pisa, Pisa, Italy. Dr. Catena is resident, Università degli Studi Firenze, [LOCATION]. Dr. Pallanti is professor of psychiatry, University of Florence, Florence, Italy, and Mount Sinai School of Medicine, New York, NY. </P> <P>Address reprint requests to: Dr. Donatella Marazziti, Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie, University of Pisa, via Roma, 67, I-56100 Pisa, Italy; or e-mail <a href="mailto:dmarazzi@psico.med.unipi.it">dmarazzi@psico.med.unipi.it</a>. </P> <P>The authors disclosed no relevant financial relationships.</P>
Referência(s)